| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | Vinblastine | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |